These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12791475)

  • 1. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
    Rodriguez Díaz JC; López M; Ruiz M; Royo G
    Int J Antimicrob Agents; 2003 Jun; 21(6):585-8. PubMed ID: 12791475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
    Rodríguez JC; Ruiz M; López M; Royo G
    Int J Antimicrob Agents; 2002 Dec; 20(6):464-7. PubMed ID: 12458143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
    Disratthakit A; Doi N
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2684-6. PubMed ID: 20368403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
    Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R
    J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
    Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
    Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria.
    Brown-Elliott BA; Crist CJ; Mann LB; Wilson RW; Wallace RJ
    Antimicrob Agents Chemother; 2003 May; 47(5):1736-8. PubMed ID: 12709349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.
    Bråbäck M; Riesbeck K; Forsgren A
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1114-6. PubMed ID: 11897601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Efficacy of Novel Oxazolidinone Analogues against Nontuberculous Mycobacteria In Vitro.
    Zhao W; Jiang Y; Bao P; Li Y; Tang L; Zhou Y; Zhao Y
    Jpn J Infect Dis; 2015; 68(6):520-2. PubMed ID: 25971324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
    Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
    Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
    García-Tapia A; Rodríguez JC; Ruiz M; Royo G
    Chemotherapy; 2004 Nov; 50(5):211-3. PubMed ID: 15523179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment.
    Abshire R; Cockrum P; Crider J; Schlech B
    Clin Ther; 2004 Feb; 26(2):191-6. PubMed ID: 15038942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2604-8. PubMed ID: 11502536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
    Leroi MJ; Siarakas S; Gottlieb T
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):72-4. PubMed ID: 11913510
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of various drugs alone or in combination against Mycobacterium fortuitum.
    Santos A; Cremades R; Rodríguez JC; Garcia-Pachon E; Ruiz M; Royo G
    J Infect Chemother; 2010 Feb; 16(1):64-7. PubMed ID: 20063030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].
    Gui J; Wang F; Hong CY; Li JL; Liang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of Linezolid against nontuberculous mycobacteria.
    Cavusoglu C; Soyler I; Akinci P
    New Microbiol; 2007 Oct; 30(4):411-4. PubMed ID: 18080676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
    von Eiff C; Peters G
    J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.
    Rodríguez JC; Cebrián L; López M; Ruiz M; Jiménez I; Royo G
    J Antimicrob Chemother; 2004 Mar; 53(3):441-4. PubMed ID: 14963069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.